These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12695423)

  • 21. [Results of clinical evidence: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)].
    Liakishev AA;
    Kardiologiia; 2003; 43(4):61-2. PubMed ID: 12968606
    [No Abstract]   [Full Text] [Related]  

  • 22. ALLHAT: definitive answers or continuing uncertainty?
    Sever P;
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):3-5. PubMed ID: 12692746
    [No Abstract]   [Full Text] [Related]  

  • 23. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: focus on the diabetic patient.
    Berecek KH; Farag A; Bahtiyar G; Rothman J; McFarlane SI
    Curr Hypertens Rep; 2004 Jun; 6(3):212-4. PubMed ID: 15128474
    [No Abstract]   [Full Text] [Related]  

  • 24. Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Taylor AL; Wright JT
    Circulation; 2005 Dec; 112(23):3654-60; discussion 3666. PubMed ID: 16330707
    [No Abstract]   [Full Text] [Related]  

  • 25. ALLHAT in perspective: implications to clinical practice and clinical trials.
    Yusoff K
    Med J Malaysia; 2005 Jun; 60(2):239-45. PubMed ID: 16114170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALLHAT: a critical assessment.
    Sjöholm A
    Blood Press; 2004; 13(2):75-9. PubMed ID: 15182109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of ALLHAT: is this the final answer regarding initial antihypertensive drug therapy?
    Moser M
    Arch Intern Med; 2003 Jun; 163(11):1269-73. PubMed ID: 12796062
    [No Abstract]   [Full Text] [Related]  

  • 28. Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT.
    Shahu A; Herrin J; Dhruva SS; Desai NR; Davis BR; Krumholz HM; Spatz ES
    J Am Heart Assoc; 2019 Aug; 8(15):e012277. PubMed ID: 31362591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
    Düsing R
    Dtsch Med Wochenschr; 2003 Jan; 128(5):214-6. PubMed ID: 12557115
    [No Abstract]   [Full Text] [Related]  

  • 30. New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial.
    Sierra C; Ruilope LM
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):169-70. PubMed ID: 14608521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
    Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?
    Beevers DG; Lee KW; Lip GY
    J Hum Hypertens; 2003 Jun; 17(6):367-72. PubMed ID: 12764397
    [No Abstract]   [Full Text] [Related]  

  • 33. [ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
    Kuwajima I
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():648-53. PubMed ID: 15171450
    [No Abstract]   [Full Text] [Related]  

  • 34. ALLHAT and ANBP2: what have we learned from recent mega-trials?
    Sander GE; Giles TD
    Am J Geriatr Cardiol; 2003; 12(4):267-71. PubMed ID: 12888711
    [No Abstract]   [Full Text] [Related]  

  • 35. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
    Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ALLHAT trial: strengths and limitations.
    Fagard RH
    J Hypertens; 2003 Feb; 21(2):229-32. PubMed ID: 12569242
    [No Abstract]   [Full Text] [Related]  

  • 37. [ALLHAT].
    Ando K
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():402-7. PubMed ID: 16981570
    [No Abstract]   [Full Text] [Related]  

  • 38. The ALLHAT trial: a verdict or a challenge?
    Zanchetti A; Mancia G
    J Hypertens; 2003 Feb; 21(2):223. PubMed ID: 12569240
    [No Abstract]   [Full Text] [Related]  

  • 39. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group
    Hypertension; 2003 Sep; 42(3):239-46. PubMed ID: 12925554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.